drugset / Trial / NCT00438802
Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Combinations of biological substances in alefacept may be able to carry cancer-killing substances directly to cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of alefacept in treating patients with relapsed or refractory cutaneous T-cell lymphoma or peripheral T-cell non-Hodgkin's lymphoma.
Timeline
- Start
- 2006-03
- Primary completion
- 2010-08-24
- Completion
- 2019-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alefacept | Protein / enzyme biologic | 0.075 mg/kg | Intravenous |
| Subject | Alefacept | Protein / enzyme biologic | 0.3 mg/kg | Intravenous |